PEG-PLGA core–shell nanoparticles for the controlled delivery of picoplatin–hydroxypropyl β-cyclodextrin inclusion complex in triple-negative breast cancer: In vitro and in vivo study

PEG-PLGA core–shell nanoparticles for the controlled delivery of picoplatin–hydroxypropyl β-cyclodextrin inclusion complex in triple-negative breast cancer: In vitro and in vivo study

In this study, we prepared an inclusion complex of picoplatin (Pc) with 2-hydroxy propyl β cyclodextrin (HPCD) to improve its hydrophilicity, yielding Pc-HPCD. The Pc-HPCD complex was encapsulated into PEG-PLGA nanoparticles (NPs) using the emulsion–solvent evaporation method, yielding Pc-HPCD@PEG-P...

Full description

Saved in:
Bibliographic Details
Main Authors: Nafie Mohamed S., Sedky Nada K., Hassan Hatem A. F. M., Fawzy Iten M., Abdelhady Manal M. M., Bakowsky Udo, Fahmy Sherif Ashraf
Format: Article
Language:English
Published: De Gruyter 2024-12-01
Series:Nanotechnology Reviews
Subjects:
picoplatin
hydroxypropyl-β-cyclodextrin
inclusion complex
peg-plga nanoparticles
cytotoxicity
apoptosis
cell cycle arrest
triple-negative breast cancer (mda-mb-231)
Online Access:https://doi.org/10.1515/ntrev-2024-0115
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items